Temozolomide

See full labeling for monitoring and dose adjustment guidelines. IV: Infuse over 90mins. Oral caps: Swallow whole with water; take on empty stomach or at bedtime to reduce nausea/vomiting, pre- and post-treat with antiemetics. Newly diagnosed glioma: Concomitant use phase: 75mg/m² (orally or by IV) once daily for 42–49 days with focal radiotherapy. Maintenance use phase (Cycle 1): start 4wks after the concomitant use phase, 150mg/m² (orally or by IV) once daily on Days 1–5 of each 28-day treatment cycle; (Cycles 2 through 6): may increase to 200mg/m² once daily on Days 1–5 if no interruptions/discontinuations required (if dose was not escalated at onset of Cycle 2, do not increase dose during Cycles 3–6). Adjuvant treatment of newly diagnosed anaplastic astrocytoma (Cycle 1): start 4wks after the end of radiotherapy, 150mg/m² (orally) once daily on Days 1–5 of each 28-day treatment cycle; (Cycles 2 through 12): increase to 200mg/m² once daily on Days 1–5 if tolerated in Cycle 1 (if dose was not escalated at onset of Cycle 2, do not increase dose during Cycles 3–6). Refractory anaplastic astrocytoma: initially 150mg/m² once daily on Days 1–5 of each 28-day treatment cycle; increase to 200mg/m² per day if ANC ≥1.5×10⁹/L and platelets ≥100×10⁹/L are reached at the nadir and on Day 1 of the next cycle; continue until disease progression or unacceptable toxicity.